Impax Laboratories — Investor Presentation (March 2007)
28 slides from Impax Laboratories's investor presentation, Mar 20, 2007
Slide 1: IMPAX Laboratories
IMPAX Laboratories, (fe. & es
Slide 2: Safe Harbor Statement
IMPAX Laboratories, Inc. (IPXL.PK) "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this presentation contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expecta
Slide 3: Company Overview
Company Overview Technology based specialty pharmaceutical company Applying oral drug delivery technology and formulation expertise to the development of generic and branded pharmaceutical products Experienced senior management team Strong product portfolio Brand strategy offers potential long-term
Slide 4: Product Portfolio
Product Portfolio Approximately 112 generic products approved, pending or under development - targeting over $30 billion in US product sales 36 Approved applications 23 Applications pending at FDA 5 ANDAs with Tentative Approval Approximately 53 more under development Additional products and/or stre
Slide 5: R&D Highlights 2006
R&D Highlights 2006 - Received 6 approvals from FDA Final Approvals for generic versions of: Salagen Colestid Granules Colestid Tablets Urecholine Ditropan XL 15mg Wellbutrin XL 300mg
Slide 6: Commercial Highlights 2006
Commercial Highlights 2006 - Launched 6 new products Includes generic versions of: Salagen 5, 7.5mg Colestid Granules Lofibra 67, 134, 200mg ProAmatine 10mg Ditropan XL 15mg Wellbutrin XL 300mg
Slide 7: Commercial Highlights 2007
Commercial Highlights 2007 - Launched one new product ^ Includes generic version of: Colestid Tablets
Slide 8: Drug Delivery Capabilities
Drug Delivery Capabilities Multiple delivery vehicles Applying new and existing drug delivery technologies to create new product opportunities (19 approved ANDAs utilize our drug delivery technologies) Developing and patenting new concepts and oral controlled release technologies Approximately 120 e
Slide 9: Development Strategy
Development Strategy Target limited competition environment Generic Controlled Release - large, rapidly growing market Specialty - technically challenging projects, barriers to entry, or other selected market opportunities Brand Targeting drugs used in treating CNS disorders Focusing on improved ver
Slide 10: Development Strategy: Outsourced Development
Development Strategy Outsourced Development Selected Generic Projects 21 development projects outsourced Utilizing 6 off-shore companies Out of the 21 projects, 6 have been submitted Provides Lower cost of development Increased development capacity
Slide 11: Generic Projects
March 2007 v1 Generic Projects IMPAX Laboratories, . tne,
Slide 12: Generic Projects Current Status
Generic Projects Current Status *US Market size, millions of US$ Group Specialty Specialty Controlled Release Controlled Release Total Total Category Qty Market* Qty Market* Qty Market* Pending at FDA 12 $842 11 $6,966 23 $7,808 Under Development 14 $3,095 39 $15,391 53 $18,486 Total 26 $3,937 50 $2
Slide 13: Paragraph IV Filing Summary (24 total)
Paragraph IV Filing Summary (24 total) Generic Projects *Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data. Note 1:Paragraph IV cert. & notice filed 4Q02. Products in Teal are marketed. White background means TA/FA rec'd. IMPAX Project G
Slide 14: Paragraph IV Filing Summary
Paragraph IV Filing Summary Generic Projects *Trademarks referenced are the property of their respective owners. **Estimation based on publicly available data. Note 2--Paragraph IV certification and notice filed 3Q05. Note 3--First to file on 15 mg strength. IMPAX Project Generic of* Est. Filing Ord
Slide 15: Paragraph IV Litigation Status Summary
Paragraph IV Litigation Status Summary (24 total filed) Generic Projects Litigation Resolved or Not Sued (17 projects) Litigation Resolved or Not Sued (17 projects) Bupropion 100,150mg ER (W) Methylphenidate 18,27,36&54mg ER Bupropion 150mg ER (Z) Carbidopa/Levodopa ER Fenofibrate 67,134,200mg Caps
Slide 16: Paragraph IV Litigation Status Summary
Paragraph IV Litigation Status Summary (24 total filed) Generic Projects Project Litigation Status Omeprazole 10, 20 & 40mg DR Trial completed June 2006; awaiting decision. Fexofenadine & PSE ER No trial date scheduled. Oxycodone 80mg ER Litigation starting. Purdue v. Endo case remanded by CAFC and
Slide 17: Commercial Strategy: Generic Alliances
Commercial Strategy Teva Signed June 2001 First product shipped 1Q 2004 12 Rx products, 11 filed to date, 11 disclosed Dava Signed November 2005 First product shipped 4Q 2005 1 Rx product, 4 Strengths, Oxycodone HCl ER Tablets; 10, 20, 40 & 80 mg Strategic Alliances for Generic Projects
Slide 18: Brand Projects
March 2007 v1 Brand Projects IMPAX Laboratories, . tne,
Slide 19: Brand Projects
Brand Projects Targeting improved versions of existing chemical entities Reduced risk and expense associated with development as compared to NCE development. Reduced time of development as compared to NCE development Utilize development and drug delivery expertise Improve patient compliance and outc
Slide 20: Brand Projects: CNS Focus
Brand Projects Focus on Central Nervous System (CNS) drugs Rapidly growing therapeutic area Focus on CNS disease states, including movement disorders such as Parkinson's disease. These movement disorders are frequently treated by the approximately 8,300 practicing neurologists, of which about 3,500
Slide 21: Brand Projects: Unmet Needs in Parkinson's
Brand Projects Despite being the standard for treating Parkinson's Disease, existing levodopa therapy does not meet certain needs: Delayed or unpredictable "on" Motor fluctuation and dyskinesias Pill burden True delivery of continuous dopaminergic stimulation
Slide 22: Brand Projects: VADOVA
Brand Projects VADOVATM (carbidopa-levodopa) is formulated with the goal of meeting one of these unmet needs by allowing a reduction in pill burden.
Slide 23: Brand Projects: VADOVA NDA Status
Brand Projects The effective date of acceptance of the VADOVA NDA by FDA was May 3, 2005. "Non-approvable" letter received from FDA March 3, 2006. An Amendment was filed on January 18, 2007 addressing the concerns raised in the Agency's non-approvable letter of March 2006. US and foreign patent appl
Slide 24: Commercial Strategy: Brand Alliances
Commercial Strategy Carbatrol (r) (Shire) Signed January 2006 Promoted Product: Carbatrol(r) (carbamazepine extended release) Payments of $40 million to be received over three years to provide promotional services Target audience - Neurologists Impax Pharmaceuticals Sales Force formed and detailing
Slide 25: Significant Milestones
Significant Milestones Milestone 2000/2001 2002 2003 2004 2005 2006 2007 (YTD) Applications Filed 16 8 8 6 10 6 2 PPG IV filings 9 5 4 1 3* 1 1 IND filings 0 0 2 1 0 0 0 NDA filings 0 0 0 0 1 0 0 Approvals (Total) 3 8 9 11 6 6 0 Tentative approval 0 5 2 2 1 1 0 Filing Goal 2007: 8-10 with focus on m
Slide 26: Financials
Financials Dec-05 Mar-06 Jun-061 Sep-06 Dec-06 (in thousands and unaudited) ___________________________________________________________________________________ Cash and Investments 56,077 41,438 30,695 27,353 29,092 Senior Debt 5,396 5,369 5,342 5,316 5,430 Convertible & Subordinated Debt 75,000 75,
Slide 27: Highlights
Highlights Experienced management with strong industry knowledge and technical expertise Broad base of drug delivery technology, formulation and development expertise Strong product portfolio Branded product strategy offers potential additional long-term growth opportunities
Slide 28: Thank you for your interest in IMPAX Laboratories, Inc.
Thank you for your interest in IMPAX Laboratories, Inc.
Impax Laboratories — Investor Presentation (March 2007) on 6ix